Harter P, Sehouli J, Vergote I, et al. - Patients with recurrent ovarian cancer are mainly treated using systemic therapy. Researchers aimed at determining the role of secondary cytoreductive surgery in their management.

• Randomized trial involving a total of 407 patients with recurrent ovarian cancer who had a first relapse after a platinum-free interval (an interval during which no platinum-based chemotherapy was used) of 6 months or more.

• Participants were randomly assigned to undergo secondary cytoreductive surgery and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone.

• Outcomes revealed longer overall survival among participants in correlation with receiving cytoreductive surgery followed by chemotherapy vs chemotherapy alone.